The Peptide and Anticoagulant Drugs Market was valued at USD 92.63 billion in 2023 and is projected to reach USD 173.99 billion by 2032, growing at a CAGR of 7.24% from 2024 to 2032. The increasing burden of cardiovascular diseases, venous thromboembolism, and other blood clotting disorders, coupled with significant advancements in peptide-based drug...